| The results of the 40,000-person trial of the shot, announced in a news release Wednesday by the German pharmaceutical company, marked a setback for a vaccine based on messenger RNA technology, the same approach at the core of the Pfizer-BioNTech and Moderna vaccines. The trial in 10 countries in Latin America and Europe, which will continue, unfolded as virus variants flourished. |
| | | | Health Alert | June 16, 4:53 p.m. EDT | | | | | The results of the 40,000-person trial of the shot, announced in a news release Wednesday by the German pharmaceutical company, marked a setback for a vaccine based on messenger RNA technology, the same approach at the core of the Pfizer-BioNTech and Moderna vaccines. The trial in 10 countries in Latin America and Europe, which will continue, unfolded as virus variants flourished. | | | | | |
